Free Trial
NASDAQ:ONVO

Organovo 8/5/2024 Earnings Report

Organovo EPS Results

Actual EPS
-$2.76
Consensus EPS
-$4.56
Beat/Miss
Beat by +$1.80
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.03 million
Beat/Miss
Beat by +$10.00 thousand
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Organovo Earnings Headlines

Two new option listings and one option delisting on April 24th
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat